Worth Venture Partners, LLC Annovis Bio, Inc. Transaction History

Worth Venture Partners, LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$9.37 - $14.12 $865,132 - $1.3 Million	-92,330 Reduced 88.23%	12,321 $116,000
Q2 2023 Aug 14, 2023	BUY	$11.95 - $16.31 $1.25 Million - $1.71 Million	104,651 New	104,651 $1.5 Million
Q4 2021 Feb 14, 2022	SELL	$17.58 - $37.67 $349,455 - $748,804	-19,878 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$30.95 - $120.97 $431,938 - $1.69 Million	-13,956 Reduced 41.25%	19,878 $631,000
Q2 2021 Aug 16, 2021	BUY	$21.55 - $96.1 $83,312 - $371,522	3,866 Added 12.9%	33,834 $2.9 Million
Q1 2021 May 17, 2021	SELL	$8.15 - $38.44 $729,995 - $3.44 Million	-89,570 Reduced 74.93%	29,968 $836,000
Q3 2020 Nov 16, 2020	SELL	$3.84 - $6.78 $77,103 - $136,135	-20,079 Reduced 14.38%	119,538 $575,000
Q2 2020 Aug 14, 2020	SELL	$2.5 - $5.64 $10,332 - $23,310	-4,133 Reduced 2.88%	139,617 $607,000
Q1 2020 May 15, 2020	BUY	$2.66 - $9.59 $382,375 - $1.38 Million	143,750 New	143,750 $432,000

1.17M

229K

934K

Ticker ANVS
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 8,163,920
Market Cap $44M
Description
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for the treatment of Alzheimer's disease (AD) and Parkinson's disease, as well as is in clinical trials for Alzheimer's disease ...

Get notified when there are updates to the investment portfolio of Worth Venture Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Worth Venture Partners, LLC with notifications on news.